Unilife — Shareholder Meeting (November 2013)
38 slides from Unilife's shareholder meeting presentation, Nov 27, 2013
Slide 1: Annual General Meeting of Stockholders November 21, 2013
Annual General Meeting of Stockholders November 21, 2013 Exhibit 99.1
Slide 2: Chairman's Welcome
Chairman’s Welcome. Mr. Jim Bosnjak.
Slide 3: Introducing our Board of Directors: In Attendance
Introducing our Board of Directors In Attendance John Lund, CPA Non-Executive Director since 2009 Chair of Audit Committee Alan Shortall CEO Executive Director since 2002 Mary Kate Wold, J.D. Non-Executive Director since 2010 Chair of Strategic Partnerships Committee William Galle Non-Executive Dire
Slide 4: Introducing our Board of Directors: Apologies
Introducing our Board of Directors Apologies Jeff Carter MApp. BFin Non-Executive Director since 2006 Based in Australia November 21, 2013
Slide 5: Agenda
Agenda 1. Confirmation of Quorum 2. Resolutions 3. Presentation from the CEO 4. Questions 5. Confirmation of Results 6. Other Business
Slide 6: Resolutions
Resolutions 1. Election of six directors 2. Ratify KPMG as independent registered public accounting firm 3. Ratify compensation paid to certain directors 4. – 8. Approve grant of securities to non-employee directors 9. Approve special grant of securities to William Galle 10. Ratify common stock issu
Slide 7: Confirmation of Quorum
Confirmation of Quorum Unilife’s quorum requirement is one-third of outstanding shares being represented either in person or by proxy At least 59.72% of the total outstanding shares entitled to vote have been received and are represented by person or proxy
Slide 8: Unilife Business Update
Unilife Business Update Unilife CEO. Mr. Alan Shortall.
Slide 9: An Innovative, Differentiated and Customizable Portfolio of Product Platforms
An Innovative, Differentiated and Customizable Portfolio of Product Platforms Confidential – Unilife Corporation Auto- Injectors Ocular Systems Wearable Injectors Reconstitution Systems Prefilled Syringes Novel Systems
Slide 10: Platform of Prefilled Syringes
Platform of Prefilled Syringes Unifill® Unifill Finesse™ Unifill Select™ Unifill Allure™ Unifill Nexus™ Fully Integrated. Highly Differentiated.
Slide 11: Sanofi Supply Contract for Lovenox
Sanofi Supply Contract for Lovenox® Unilife Product: Unifill Finesse - customized product from Unifill platform Sanofi Drug: Enoxaparin Sodium (Lovenox® / Clexane®) Drug Area: Anti-thrombotics (low molecular weight heparin) Geographic Territory: Global Contract Period: Can extend up to 2024 Exclusiv
Slide 12: Market for Generic Injectables
Market for Generic Injectables $11 B global market for global generic injectables (13% CAGR to 2017) The U.S. accounts for $7 B (60%) of the global market 1.5 B doses of generic injectable drugs used in the U.S. every year About 70% of U.S. hospital patients receive a generic injectable drug Rapid c
Slide 13: The Unifill Nexus
The Unifill Nexus™ Universal Connectivity. No Clogging. No Breakage. Standard Fill Finish Luer collar fits any standard needle or connector No Clogging or Breakage Safe, Intuitive, One-Handed
Slide 14: Commercial Supply Contract with Hikma
Commercial Supply Contract with Hikma Hikma is rd largest by volume in the US generic injectables market 15 Year supply agreement to launch 20 generic injectable drugs in syringes from Unifill platform including Unifill and Unifill Nexus Hikma to receive exclusivity for use of Unilife devices with t
Slide 15: Platform of Reconstitution Systems
Platform of Reconstitution Systems One-Step Reconstitution. A World of Differentiation. AutoMix Presto™ EZMix Genesis™ EZMix Engage™ EZMix Prodigy™
Slide 16: The EZMix Prodigy
The EZMix Prodigy™ Compact, integrated single-barrel design for doses between 1-50mL Intuitive single-step reconstitution for liquid or dry drug combinations Being pursued by multiple pharmaceutical and biotech customers
Slide 17: Platform of Auto-Injectors
Platform of Auto-Injectors LISA™ smart reusable auto-injector RITA™ disposable auto-injector Self-Injection. Simplified. Multiple programs underway that are aligned with Unifill syringe products
Slide 18: The Market for Wearable Injectors
The Market for Wearable Injectors Around 250 high viscous, large volume biologics targeted for wearable injectors Multiple therapy areas targeted including cancer and auto-immune diseases List includes 100+ pharma and biotech companies Estimated 350 million wearable injectors to be sold annually by
Slide 19: Platform of Wearable Injectors
Platform of Wearable Injectors Pre-Filled. Pre-Assembled. Ready - to - Inject. Precision-Therapy™ Flex-Therapy™ For long-duration therapies that require delivery of large dose volumes For long-duration therapies that require delivery of large dose volumes with a specific rate profile
Slide 20: A Typical Customer Partnership
A Typical Customer Partnership Average number of drugs being targeted 3 – Average phase of drugs being targeted Late-stage Average unit volume range per molecule 2 - 5MM units Average customization program length 18 - 36 months Average size of customization program per drug per year $3 - 6MM* Averag
Slide 21: Customization and Supply Contract with MedImmune
Customization and Supply Contract with MedImmune MedImmune is the global biologics R&D arm of AstraZeneca One of the richest biologic portfolios in the industry 120 large molecule drugs in R&D (half of AstraZeneca’s total clinical pipeline) Under this agreement, Unilife will customize and supply dev
Slide 22: Ocular Delivery and Novel Device Platforms
Ocular Delivery and Novel Device Platforms Ocu-ject™ Micro-ject™ Beyond Conventional Delivery Systems Depot-ject™
Slide 23: Moving Forward
Moving Forward Revenue to grow sequentially each and every quarter in FY 2014 Significant annual revenue growth this fiscal year and beyond Down the road, as contracts reach peak commercial sales, we will attain a position of global leadership for injectable drug delivery Prefilled Syringes: Targeti
Slide 24: Consider and Vote for Matters set forth in Proxy Statement
Annual General Meeting of Stockholders November 21, 2013 Consider and Vote for Matters set forth in Proxy Statement
Slide 25: Election of Directors
Election of Directors Item 1.
Slide 26: Election of Directors: Item 1 Results
For Withheld Election of Directors Item 1. Item 1.1 Jim Bosnjak 37,893,553 89.64% 4,381,120 10.36% Item 1.2 Jeff Carter 38,248,088 90.48% 4,026,585 9.52% Item 1.3 William Galle 39,975,506 94.56% 2,299,167 5.44% Item 1.4 John Lund 39,968,156 94.54% 2,306,517 5.46% Item 1.5 Mary Kate Wold 40,048,663 9
Slide 27: Item 2. Ratification of KPMG LLP
Item 2. Ratification of the appointment of KPMG LLP as the Corporation’s independent registered public accounting firm for Fiscal Year 2014
Slide 28: Item 2 Results
For Against Abstain Item 2. Ratification of the appointment of KPMG LLP as the Corporation’s independent registered public accounting firm for Fiscal Year 2014 Item 2. 58,319,458 904,285 684,984
Slide 29: Item 3. Advisory Vote on Executive Compensation
Item 3. To consider and act on an advisory vote regarding the approval and compensation paid to certain executive officers
Slide 30: Item 3 Results
For Against Abstain Item 3. Item 3. 36,033,719 5,784,484 456,470 To consider and act on an advisory vote regarding the approval and compensation paid to certain executive officers
Slide 31: Items 4-8. Grants to Non-Employee Directors
Items 4 - 8. The approval of the grant of 105,000 securities to each of the five non-employee Directors
Slide 32: Items 4-8 Results
For Against Abstain Items 4 - 8. Item 4. Jim Bosnjak 30,270,781 11,676,609 327,283 Item 5. Jeff Carter 30,130,410 11,683,867 460,396 Item 6. William Galle 30,410,105 11,400,255 464,313 Item 7. John Lund 30,410,221 11,400,755 463,697 Item 8. Mary Kate Wold 30,433,812 11,382,098 458,763 The approval o
Slide 33: Item 9. Special Grant to William Galle
Item 9. To approve a special grant of 52,500 securities to William Galle in the form of restricted stock units.
Slide 34: Item 9 Results
For Against Abstain Item 9. Item 9. 30,306,626 11,483,493 484,554 To approve a special grant of 52,500 securities to William Galle in the form of restricted stock units.
Slide 35: Item 10. Ratify Common Stock Issuance under Cantor Agreement
To ratify the issuance and sale of 3,512,153 shares of common stock (equivalent to 21,072,918 CHESS Depositary Interests (“CDIs”)) under the Controlled Equity Offering Sales Agreement we entered into with Cantor Fitzgerald & Co. dated October 3, 2012, pursuant to a registration statement filed by us
Slide 36: Item 10 Results
For Against Abstain To ratify the issuance and sale of 3,512,153 shares of common stock (equivalent to 21,072,918 CHESS Depositary Interests (“CDIs”)) under the Controlled Equity Offering Sales Agreement we entered into with Cantor Fitzgerald & Co. dated October 3, 2012, pursuant to a registration s
Slide 37: Other Business
Annual General Meeting of Stockholders November 21, 2013 Other Business
Slide 38: Close of Meeting
Annual General Meeting of Stockholders November 21, 2013 Close of Meeting